Diamond Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Diamond therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Diamond Therapeutics Today - Breaking & Trending Today

Bellevue Group AG Has $23.99 Million Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Bellevue Group AG grew its holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Free Report) by 4.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,535,839 shares of the company’s stock after buying an additional 400,000 shares during the quarter. Bellevue […] ....

Bellevue Group , Citigroup Inc , Jump Financial , Cornercap Investment Counsel Inc , Algert Global , Diamond Therapeutics Inc , Black Diamond Therapeutics , Free Report , Fire Capital , Cornercap Investment Counsel , Diamond Therapeutics , Get Free Report , Black Diamond Therapeutics Daily ,

Black Diamond Therapeutics Presents Promising BDTX-1535

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging. ....

United Kingdom , Black Diamond , United States , Patrick Wen , Nader Sanai , Mario Corso , International Conference On Molecular , Ivy Brain Tumor Center , Diamond Therapeutics Inc , Company Masterkey , American Society Of Clinical Oncology , Oncology At Dana Farber Cancer Institute , Exchange Commission , Diamond Therapeutics , American Society , Clinical Oncology , Dana Farber Cancer , Generation Covalent , Recurrent Glioblastoma , Dose Escalation Results , Molecular Targets , Trigger Trial , Recurrent High Grade Glioma , Ivy Brain Tumor , Private Securities Litigation Reform Act , Annual Report ,

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment . ....

United States , United Kingdom , Black Diamond , Nader Sanai , Patrick Wen , Mario Corso , Ivy Brain Tumor Center , International Conference On Molecular , Globenewswire Inc , Exchange Commission , American Society Of Clinical Oncology , Diamond Therapeutics Inc , Dana Farber Cancer Institute , Company Masterkey , Diamond Therapeutics , Clinical Oncology , Farber Cancer , Generation Covalent , Recurrent Glioblastoma , Dose Escalation Results , Molecular Targets , Trigger Trial , Recurrent High Grade Glioma , Ivy Brain Tumor , Private Securities Litigation Reform Act , Annual Report ,

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with ...

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment ....

Black Diamond , United States , United Kingdom , Patrick Wen , Nader Sanai , Mario Corso , American Society Of Clinical Oncology , Exchange Commission , Ivy Brain Tumor Center , Oncology At Dana Farber Cancer Institute , Diamond Therapeutics Inc , International Conference On Molecular , Company Masterkey , Diamond Therapeutics , American Society , Clinical Oncology , Dana Farber Cancer , Generation Covalent , Recurrent Glioblastoma , Dose Escalation Results , Molecular Targets , Trigger Trial , Recurrent High Grade Glioma , Ivy Brain Tumor , Private Securities Litigation Reform Act , Annual Report ,

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data In Patients With Recurrent Glioblastoma At 2024 American Society Of Clinical Onc...

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging ant ....

United States , United Kingdom , Black Diamond , Patrick Wen , Nader Sanai , Mario Corso , American Society Of Clinical Oncology , Oncology At Dana Farber Cancer Institute , Ivy Brain Tumor Center Clinical , Ivy Brain Tumor Center , Company Masterkey , International Conference On Molecular , Diamond Therapeutics Inc , Exchange Commission , Diamond Therapeutics , American Society , Clinical Oncology , Dana Farber Cancer Institute , Generation Covalent , Recurrent Glioblastoma , Dose Escalation Results , Molecular Targets , Trigger Trial , Recurrent High Grade Glioma , Private Securities Litigation Reform Act , Annual Report ,